Table 1.

Levodopa pharmacodynamic parameters in de novo (untreated), stable and fluctuating (chronically treated) patients

Source	Patient group	E0 (taps/min)	Dmax (taps/min)	Emax (taps/min)	EC50 (µmol/L)	Hill coefficient	Teqf (h)
[5] MKMODEL	De novo chronic	91±31	46±61	137±62	5.39±2.83	1.30±0.6	3.99±6.0
		95±32	51±39	146±50	4.60±3.56	2.24±1.3	0.63±0.57
[21] MKMODEL	Mean data	110	53.2	163.2	2.94	–	0.388
[22] MKMODEL	De novo stable Fluctuating	116±9	44±34	–	12.7±7.4	6.3±8.0	–
		144±25	56±28		11.6±7.6	1.3±0.8
		106±23	98±17		10.7±7.2	1.4±0.8
[23] SIPHAR	Chronic 2nd dose ≥3 h after 1st dose	101±39	77±47	–	–	–	0.42±0.17
		101±39	76±41				0.33±0.21
[24] SIPHAR	Stable fluctuating	101±33	40.5±18.3	166±44	1.22±0.66 (iv)	2.8±1.5	2.72±1.17
		125±34	51.5±25.0	153±44	3.25±1.32	16.3±12.7	0.48±0.35
[25] NONMEM	Population	–	90 (fixed)	–	1.78±3.5%	0.8±15.1%	2.89±0.03%

From [5].